SUMMARY Seventy three sisters of boys with Duchenne muscular dystrophy and their families were studied using up to seven deoxyribonucleic acid (DNA) probes linked to the gene on the short arm of the X chromosome. Fifty three (73%) were informative for flanking markers, a further 18 (24%) being informative for a single marker only.
SUMMARY Seventy three sisters of boys with Duchenne muscular dystrophy and their families were studied using up to seven deoxyribonucleic acid (DNA) probes linked to the gene on the short arm of the X chromosome. Fifty three (73%) were informative for flanking markers, a further 18 (24%) being informative for a single marker only.
Predictions based on pedigree structure and creatine kinase information from the individuals and their female relatives gave more than half (55%) of the sisters a risk for being a carrier of below 10% or above 90%. The addition of information derived from the inheritance of flanking DNA markers, where they exist, improves the situation so that many more sisters (77%) can be allocated into either high or low risk categories.
The estimation of risk for carrier state in female relatives of boys with the X linked Duchenne muscular dystrophy has been based up to now on pedigree analysis, combined with information derived from creatine kinase studies.
For many women at risk this combination can give a reasonable resolution into either 'high' or 'low' risk categories. A considerable number, however, are left in an indeterminate position with consequent uncertainty for decisions concerning childbearing.
For risk prediction accurate pedigree analysis is the first essential, and, although fairly straightforward in some circumstances, the opportunity for error in more extended families is considerable.' 2 The interpretation of data on creatine kinase activity is also not without its pitfalls. Results have to be interpreted in the light of well established ranges for normal women and obligatory carriers, so that the probability of being a carrier at any level can be expressed as a likelihood ratio, which will modify the prior risk (whether 'high' or 'low') derived from the pedigree analysis. Figure 1 illustrates the alteration in risk distribution of the 71 informative girls when various combinations of pedigree, creatine kinase, and DNA data are taken into consideration for risk estimation.
Figure 1(a) shows the risk distribution for the 71 individuals based on all pedigree and creatine kinase data from relatives, but before their own personal creatine kinase or DNA data are included. Most have a risk close to 50%, being the daughters of obligatory carriers, or of women whose creatine kinase activity is so high that they are presumed to be carriers. Lower values result for sisters of isolated cases, where the presence of normal male relatives and female relatives with values of creatine kinase activity in the normal range make the possibility of a new mutation more likely.
Figure 1 (b) shows that the addition of personal creatine kinase information has resulted in a partial separation into a high or low risk group. The separation at the low risk end is less clear because of the extensive overlap of normal and carrier ranges. DNA probe data, shown in Figure 1 (c), likewise gives a partial separation but without preference for either end. The apparent preference for the lower risk end is due to those girls already in the lower risk groups. Combining the use of creatine kinase and DNA information (Fig. 1(d) ) gives a considerably enhanced separation into high and low risk groups.
Discussion
Pedigree analysis supported by creatine kinase data from all available female relatives has up to now been the mainstay of risk estimation for women in Duchenne families.
When all available pedigree information is combined with likelihood ratios derived from knowledge of the creatine kinase distribution of obligate carriers and normals in the same population around half of the 73 sisters in this series could be given a reasonably definite risk state (<10% or >90%). The other half, however, are still left with risk estimates in the intermediate range ( Fig. 1(b) ).
Information derived from DNA markers can also be used in risk predictions, with an accuracy related to the genetic distance of the linked marker from the disease locus. The closer the flanking markers are to the disease gene, the more accurate will be the predictions.
Using DNA and pedigree information without creatine kinase data the total number of individuals that can be allocated into high or low risk categories is rather less than on using creatine kinase and pedigree data alone, but the separation is greater in the low risk groups, for which normal creatine kinase values give much less discrimination on account of the extensive overlap between carrier and normal creatine kinase ranges. Thus DNA information will be of especial value in those high risk individuals with creatine kinase values in the normal range, while creatine kinase data will continue to be of great value when considerably raised activities are present, emphasising the need for both forms of testing to be used in combination.
In our study the combination of pedigree, creatine kinase, and DNA data, when identifiable flanking markers exist, shows that almost 80% of sisters of boys with Duchenne muscular dystrophy can be given a definitively high (>90%) or low (<10%) risk estimate (Table 3) . Taking the 53 girls informative for flanking markers, only 12 remained in risk groups between 10% and 90% (Table 3 and Fig. 2 ). For all 12 DNA information was only available for two generations, and in all but two crossovers had occurred.
Both these factors introduce uncertainty into the use of DNA probe data, but closer markers will improve this position, although there will remain a small number who, because of the paucity of family members available for testing, will not be helped to the maximum possible extent.
The overall risk distributions shown in Figure 1 do not fully reflect how risks have been altered for specific individuals. This aspect is illustrated in Table 4 . It can be seen that in none of the cases has the addition of DNA data caused a radical revision of risk estimates previously given on the basis of pedigree information. The general effect of the added information is to clarify the position by reducing further the risks of those already placed in low risk groups and the opposite for high risk individuals. Thus 34% of women can now be given a risk of less than 5% of being a carrier, one third of whom had risk estimates of greater than 5% without the DNA information.
As expected it is the individuals who were previously placed in the intermediate risk groups who derive most benefit from the additional information. This absence of radical reclassification of carrier state is reassuring for two reasons: it supports the validity of the new approach to risk estimation by use of DNA probes, but it also means that definitive results based on creatine kinase activity, the only method available in most centres, will continue to be valid.
It has been suggested that flanking markers could be useful for accurate prenatal diagnosis, and one case in which this approach has been applied has recently been reported.9 Considerable caution, however, should be exercised in this respect. The Risk estimate (%) Fig. 2 Comparison ofthe distribution ofrisks of (a) the total number ofsisters informative (n= 71) with (b) the 53 sisters informative forflanking markers. group.bmj.com on October 13, 2017 -Published by http://adc.bmj.com/ Downloaded from exact genetic distances of these markers are still not certain, with considerable differences existing at present between estimates from various laboratories. In particular, the probe 754, thought by some to be a distance of roughly 3 centimorgans from the Duchenne locus.,9 gives a distance of 21 centimorgans when tested in a large panel of our Duchenne families. A provisional distance based on pooled data from different centres is roughly 10 centimorgans. Potential error resulting from such uncertainty is particularly important in prenatal diagnosis, where decisions on termination of pregnancy are involved, and where DNA information cannot be combined with creatine kinase data to give a more accurate result.
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It is also apparent that in any series of families only a few will have the ideal three generation structure available to produce the best possible prediction.
Although for many families and individuals the small margin of error inherent in the use of closely linked and highly polymorphic markers might be acceptable, general use of DNA probes in prenatal diagnosis will probably need to await the discovery of probes specific to the Duchenne muscular dystrophy region.
The number of flanking probes is being added to continually, thereby increasing the number of women who can be helped by these methods. Probes more closely related to the Duchenne muscular dystrophy gene are also now becoming available, notably that reported by Monaco et all" since completion of this work. This sequence identifies actual deletions of the Duchenne gene in a small proportion of affected individuals and is likely to provide a marker showing less recombination than any of the probes identified by conventional linkage studies.
Conclusions
The existing DNA markers flanking the Duchenne muscular dystrophy locus have added a useful contribution to the prediction of carrier state in sisters of boys with the dystrophy. In our experience the combined data can give a clear indication of carrier state for about 80% of these individuals. Our results emphasise the continuing need for carefully performed and interpreted creatine kinase studies and show the importance of integrating the various types of information in making a final risk estimation. The probes available at present will not provide, except in rare circumstances, sufficiently accurate information for satisfactory prenatal diagnosis.
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